Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus

被引:362
作者
Cui, L
Ma, XX
Sato, K
Okuma, K
Tenover, FC
Mamizuka, EM
Gemmell, CG
Kim, MN
Ploy, MC
El Solh, N
Ferraz, V
Hiramatsu, K
机构
[1] Juntendo Univ, Fac Med, Dept Bacteriol, Bunkyo Ku, Tokyo 1138421, Japan
[2] Juntendo Univ, Fac Med, Ctr Electron Microscopy, Bunkyo Ku, Tokyo 1138421, Japan
[3] Ctr Dis Control & Prevent, Div Hlth Care Qual Promot, Atlanta, GA USA
[4] Univ Sao Paulo, Sch Pharmaceut Sci, Sao Paulo, Brazil
[5] Univ Glasgow, Glasgow Royal Infirm, Sch Med, Dept Bacteriol, Glasgow G31 2ER, Lanark, Scotland
[6] Univ Ulsan, Coll Med, Dept Clin Pathol, Seoul, South Korea
[7] Asan Med Ctr, Seoul, South Korea
[8] CHU Dupuytren, Dept Bacteriol, F-87042 Limoges, France
[9] Inst Pasteur, French Natl Reference Ctr Staphylococci, Unite Staphylocoques, F-75724 Paris 15, France
[10] S African Inst Med Res, Dept Clin Microbiol & Infect Dis, Johannesburg, South Africa
[11] Univ Witwatersrand, Johannesburg, South Africa
关键词
D O I
10.1128/JCM.41.1.5-14.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We have previously shown that a thickened cell wall is responsible for the vancomycin resistance of vancomycin-resistant Staphylococcus aureus (VRSA) (equivalent to vancomycin-intermediate S. aureus and glycopeptide-intermediate S. aureus) strain Mu50 (L. Cui, H. Murakami, K. Kuwahara-Arai, H. Hanaki, and, K. Hiramatsu, Antimicrob. Agents Chemother. 44:2276-2285, 2000). However, the mechanism of vancomycin resistance in other VRSA strains remained unclear. In this study, 16 clinical VRSA strains from seven countries were subjected to serial daily passage in drug-free medium. After 10 to 84 days of passage in the nonselective medium, passage-derived strains with decreased MICs of vancomycin (MIC, <4 mg/liter) were obtained. However, all of the passage-derived strains except one (15 of 16) still possessed subpopulations that were resistant to vancomycin as judged by population analysis, and vancomycin-resistant mutant strains were selected from the passage-derived strains by one-step vancomycin selection with a frequency of 4.25 X 10(-6) to 1.64 X 10(-3). The data indicated that vancomycin-resistant cells are frequently generated from the passage-derived strains even after vancomycin selective pressure is lifted. Cell wall thicknesses and MICs of glycopeptides (vancomycin and teicoplanin) and beta-lactams (imipenem and oxacillin) were determined for a total of 48 strains, including 15 sets of three strains: the clinical VRSA strain, the passage-derived strain, and the vancomycin-resistant mutant strain obtained from the passage-derived strain. No simple correlation between glycopeptide and beta-lactam MICs was seen, while significant correlations between MICs of vancomycin and teicoplanin (r = 0.679; P < 0.001) and between MICs of imipenem and oxacillin (r = 0.787; P < 0.001) were recognized. Moreover, all of the VRSA strains had significantly thickened cell walls, which became thinner with the loss of vancomycin resistance during drug-free passages and again became thick in the resistant mutant strains. The data showed that cell wall thickness had high correlation with the MICs of the two glycopeptides (correlation coefficients, 0.908 for vancomycin and 0.655 for teicoplanin) but not with those of the beta-lactam antibiotics tested. These results together with coupled changes of cell wall thickness and vancomycin MICs in 16 isogenic sets of strains indicate that thickening of the cell wall is a common phenotype of clinical VRSA strains and may be a phenotypic determinant for vancomycin resistance in S. aureus.
引用
收藏
页码:5 / 14
页数:10
相关论文
共 35 条
[1]  
[Anonymous], 1995, J INFECT CHEMOTHER
[2]   Combination effect of vancomycin and β-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin [J].
Aritaka, N ;
Hanaki, H ;
Cui, LZ ;
Hiramatsu, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (04) :1292-1294
[3]   Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates [J].
Boyle-Vavra, S ;
Berke, SK ;
Lee, JC ;
Daum, RS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) :272-277
[4]   A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates [J].
Boyle-Vavra, S ;
Labischinski, H ;
Ebert, CC ;
Ehlert, K ;
Daum, RS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :280-287
[5]   Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic [J].
Breukink, E ;
Wiedemann, I ;
van Kraaij, C ;
Kuipers, OP ;
Sahl, HG ;
de Kruijff, B .
SCIENCE, 1999, 286 (5448) :2361-2364
[6]   Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals [J].
Chesneau, O ;
Morvan, A ;
El Solh, N .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (06) :887-890
[7]   Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50 [J].
Cui, LZ ;
Murakami, H ;
Kuwahara-Arai, K ;
Hanaki, H ;
Hiramatsu, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2276-2285
[8]  
Ferraz V, 2000, S AFR MED J, V90, P1113
[9]   Conversion of oxacillin-resistant staphylococci from heterotypic to homotypic resistance expression [J].
Finan, JE ;
Rosato, AE ;
Dickinson, TM ;
Ko, D ;
Archer, GL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (01) :24-30
[10]  
Fridkin SK, 2001, CLIN INFECT DIS, V32, P108, DOI 10.1086/317542